Cabometyx 40 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FCFM8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,644
Award facts
- Contract value 100% obligated
- $33,644.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $33,644.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Cabometyx 40 mg tablets (30-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of December 22, 2025, and carries no set-aside designation. This award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide. The parent contract, valued at $499,999,999 and effective through December 31, 2036, was awarded on November 13, 2025, and includes a 30-month base period with three 30-month option periods.
DMS Pharmaceutical Group has demonstrated substantial performance capacity across the federal pharmaceutical supply chain, with delivery orders ranging from under $100 to over $115,000 since October 2025. The company specializes in distributing an extensive portfolio of branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support military medical operations. As a critical regional pharmaceutical supplier under the PPV-G GEN V framework, DMS Pharmaceutical Group leverages its small business status to compete effectively in unrestricted federal procurement while maintaining consistent performance across multiple therapeutic categories, including oncology treatments, immunosuppressants, emergency medications, and routine pharmaceuticals required by the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FCFM8?
SPE2DR26FCFM8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26FCFM8 worth?
The government has obligated $33,644 on SPE2DR26FCFM8.
Is contract SPE2DR26FCFM8 an order under another contract?
Yes. SPE2DR26FCFM8 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFM8 competed?
The extent of competition for SPE2DR26FCFM8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award